A Phase 1 Open-Label Study of the Safety, Tolerability and Efficacy of KPT-9274, a Dual Inhibitor of PAK4 and NAMPT, in Patients With Advanced Solid Malignancies or Non-Hodgkin's Lymphoma

Trial Profile

A Phase 1 Open-Label Study of the Safety, Tolerability and Efficacy of KPT-9274, a Dual Inhibitor of PAK4 and NAMPT, in Patients With Advanced Solid Malignancies or Non-Hodgkin's Lymphoma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Sep 2017

At a glance

  • Drugs KPT 9274 (Primary) ; Niacin
  • Indications Colon cancer; Lung cancer; Non-Hodgkin's lymphoma; Sarcoma; Solid tumours
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms PANAMA
  • Sponsors Karyopharm Therapeutics
  • Most Recent Events

    • 12 Sep 2017 Results (n=14; as of 2 Mar 2017) presented at the 42nd European Society for Medical Oncology Congress
    • 08 Sep 2017 Results (n = 21) published in a Karyopharm Therapeutics media release.
    • 30 Aug 2017 Results from this trial will be presented at the European Society of Medical Oncology (ESMO) 2017 Annual Meeting, according to a Karyopharm Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top